Aug 17, 2026 · 6 min
Mining gains meet drug-trial surprises across European markets
Fresnillo AstraZeneca Climbs, Argenx Surges
The episode shows how commodity strength, clinical setbacks, and late-stage drug success can move shares in sharply different directions.
- 1Copper and gold strength lifts British mining stocks, including Fresnillo, as competition for supply intensifies.
- 2AstraZeneca gains despite stopping a lung-cancer trial that failed to outperform existing therapies.
- 3Argenx surges on late-stage immune-disease results that could support US approval and reduce reliance on immunosuppressants.
Don't miss
Argenx shares surge after positive late-stage results for an immune-disease treatment, potentially opening a path toward US approval.
The brief
British mining stocks rise as copper approaches record levels and gold remains supportive, putting Fresnillo and other precious-metals producers in focus.
AstraZeneca shares climb despite a setback in oncology: the company halted a lung-cancer drug trial after it failed to beat existing therapies.
Argenx delivers the episode’s sharpest move, surging after positive late-stage results for an immune-disease treatment that could support US approval.
The report ends by previewing a broader discussion with Jacob Greaves on AI, urban development, and Dubai’s long-term response to rapid population growth.
Together, the market moves show how investors can reward commodity exposure and clinical progress while treating a trial failure as a contained setback.
What was said on this episode
7 statements · 6 positive · 1 negative
Copper prices are approaching record highs.
“Copper is rising towards record highs.”
Listen at 0:59
Gold prices are rising.
“And gold is also rising.”
Listen at 1:10
Mining stocks are performing strongly overall.
“So overall, strong performance for miners.”
Listen at 1:24
The failed trial is a slight setback for AstraZeneca.
“So, a slight setback there.”
Listen at 2:02
Argenx shares rose as much as 10%.
“shares up as much as 10%.”
Listen at 2:45
Argenx's drug helps patients with an immune-system disease.
“this helps patients with an immune system disease.”
Listen at 2:53
AI will compress processes in smart-city systems.
“AI will allow in the smart city space to compress a lot of things.”
Listen at 4:00
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Bloomberg L.P.Listen to the full episode and explore every guest, topic, and moment on PodLume.